Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

NCT02421094 is registered in ClinicalTrials.gov with Galectin Therapeutics Inc. as lead sponsor.

NCT NCT02421094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02421094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Lead sponsor
Galectin Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
September 27, 2016
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis